Sensimed CEO Discloses Financing, Next Steps

Sensimed CEO David Bailey recounts his maiden presentation to OIS and shares information on the company’s recent financing, including a commitment from a new strategic investor. He also explains why ocular volume change could be a clinically relevant measurement for glaucoma.


David Bailey

Barry Cheskin

David Bailey has over 30 years of executive experience across major corporations and geographies in the Medical Device and Pharmaceutical industry including seven years as CEO of a USA public company.

View Full Profile